1214 / 1631
StiL NHL 7-2008: Rationale
Bendamustine plus Rituximab (B-R) is an established 1st-line treatment
in low-grade lymphomas including Follicular lymphoma (FL), Waldenström,
Small Lymphocytic Lymphoma (SLL) and Marginal Zone Lymphomas (MZL)
Rituximab (R) maintenance improves PFS after R-chemoimunotherapy in FL
- PRIMA trial, randomized to that effect
- BRIGHT trial, not randomized, R was given at investigator’s discretion
- StiL M
AINTAIN
trial, not randomized, historical control to StiL NHL1
No randomized data available for R-maintenance in MZL,
thus, the role of 2 years R-maintenance after R-chemo is unclear in MZL
R-maintenance as an attempt to further prolong disease control after B-R